$AVBP News
Last published 2d ago
- 2d agoAVBPArriVent BioPharma, Inc. - EXHIBIT 99.1Earnings ReleasesForm 8-K - Current report - Item 2.02 Item 5.02 Item 9.01
- 2d agoAVBPArriVent BioPharma Reports Third Quarter 2026 Financial ResultsGlobeNewswireNEWTOWN SQUARE, Pa., Nov. 09, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today reported financial results for the third quarter ended September 30, 2026, and highlighted recent Company progress.
- 2d agoAVBPArriVent BioPharma Reports Third Quarter 2026 Financial ResultsGlobeNewswireContinued enrollment in pivotal Phase 3 ALPACCA study in EGFR PACC-mutant NSCLCPresented encouraging Phase 1 data for ARR-217, a CDH17-targeted ADC for gastrointestinal malignancies at ESMODosed first patient in U.S.
- 2w agoNTHIAVBPXNCRDefining Moments in the Race for Biotech BreakthroughsGlobeNewswireDENVER, Oct. 26, 2026 (GLOBE NEWSWIRE) -- (247marketnews.com) — These biotechnology companies are advancing important developments. NeOnc Technologies Holdings (NASDAQ:NTHI) is outlining plans for a major
- 2w agoAVBPArriVent Announces Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at ESMO Congress 2026GlobeNewswire44.8% ORR at 6mg/kg dose in late-line CRC patients ARR-217 was generally well-tolerated ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN
- 2w agoAVBPArriVent to Present Initial Phase 1 Data for CDH17-targeted ADC ARR-217 in Patients with Gastrointestinal Cancers at the ESMO Congress 2026GlobeNewswireFirst-in-human data for ARR-217 selected as a late-breaking oral presentation ArriVent to host virtual webinar on Monday, October 26, 2026, at 8 am ET to discuss the data from the ARR-217 program NEWTOWN SQUARE, Pa.,
- 3w agoAVBPArriVent Announces Cancer Cell Publication Highlighting Firmonertinib in EGFR PACC-Mutant Non-Small Cell Lung CancerGlobeNewswireNEWTOWN SQUARE, Pa., Oct. 19, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
- 4w agoAVBPARRIVENT BIOPHARMA INVESTIGATION: AVBP Securities Investors Encouraged to Contact Kirby McInerney LLP About Their RightsGlobeNewswireNEW YORK, Oct. 13, 2026 (GLOBE NEWSWIRE) -- The law firm of Kirby McInerney LLP is investigating potential claims against Arrivent BioPharma ("Arrivent" or the "Company") (NASDAQ:AVBP). The
- 1mo agoAVBPArriVent Announces First Patient Dosed with Novel Tetravalent MUC16/NaPi2b Dual Target ADC, ARR-002GlobeNewswireNEWTOWN SQUARE, Pa., Oct. 12, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
- 3mo agoAVBPArriVent BioPharma Reports Second Quarter 2026 Financial ResultsGlobeNewswireTopline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected 2H 2026ARR-217, a CDH17 targeted ADC for gastrointestinal malignancies, advanced to Phase 1b dose
- 6mo agoAVBPArriVent BioPharma Reports First Quarter 2026 Financial ResultsGlobeNewswireTopline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026IND clearance of ARR-002, ArriVent's dual-targeting MUC16/NaPi2b tetravalent ADC, advances into the
- 6mo agoAVBPArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial CancersGlobeNewswireSuperior efficacy and favorable tolerability in animal models support the potential of ARR-002 to overcome limitations of single-target approachesPhase 1 initiation expected in the second half of 2026 NEWTOWN SQUARE,
- 7mo agoAVBPAarvik Therapeutics Showcases Novel ADC Molecules Based On MUTTA™ and AQUALINK™ Platforms at AACR 2026Business WireAarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, is pleased to announce that it will present two posters and a minisymposium talk at
- 8mo agoAVBPArriVent BioPharma Reports Full Year 2025 Financial ResultsGlobeNewswireTopline global pivotal Phase 3 data for firmonertinib in first-line EGFR exon 20 insertion mutant NSCLC expected mid-2026Global pivotal Phase 3 first-line PACC mutant NSCLC study for firmonertinib enrollment underwayADC
- 9mo agoAVBPSMMTMRUSMRK+9EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsightPR NewswireDelveInsight's EGFR-NSCLC Market Insights report includes a comprehensive understanding of current treatment practices, EGFR-NSCLC emerging drugs,...
- 9mo agoONCYRLAYMAIAZLAB+1$207B Market Shift: The Race for Fast Track Approval in OncologyPR NewswireUSANewsGroup.com News Commentary – The FDA isn't just approving drugs; they are completely reshaping the landscape. In 2025 alone, the agency issued...
- 10mo agoONCYCGONZNTLAVBP+1Fast-Tracking the $537B Cancer Cure: How Accelerated Approvals Reshaping Oncology in 2026PR NewswireUSANewsGroup.com News Commentary – The oncology landscape is entering a high-velocity regulatory phase as genomics in cancer care expands toward a...
- 10mo agoAVBPArriVent Announces First Patient Dosed in Global Pivotal Phase 3 ALPACCA Trial Evaluating Firmonertinib for First-Line Treatment of EGFR PACC Mutant Non-Small Cell Lung CancerGlobeNewswireFirmonertinib has the potential to redefine first-line treatment in this underserved population as a once daily, oral, brain-penetrant, chemo-free monotherapyALPACCA pivotal trial is designed to support potential
- 11mo agoONCYAIMAVBPMRUS+1Immunotherapy Breakthroughs Turn Cold GI Tumors Hot as Market Tops $443BPR NewswireUSANewsGroup.com News Commentary – Gastrointestinal cancers that once resisted checkpoint inhibitors are finally responding to novel combination...
- 1y agoAVBPArriVent BioPharma Reports Third Quarter 2025 Financial ResultsGlobeNewswireFinal Phase 1b results presented at World Lung Conference highlight the potential of firmonertinib to address unmet needs in EGFR PACC mutant NSCLC Received FDA IND clearance for ARR-217, a CDH-17 targeted ADC, with
- 1y agoAVBPArriVent Appoints Brent S. Rice as Chief Commercial OfficerGlobeNewswireNEWTOWN SQUARE, Pa., Sept. 22, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
- 1y agoAVBPArrivent Presents the Final Analysis of Firmonertinib Monotherapy Data from Global Phase 1b Study in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2025 World Conference on Lung CancerGlobeNewswire16.0 months median progression free survival (mPFS) with firmonertinib 240 mg by blinded independent central review (BICR) in first-line patientsConfirmed overall response rate (cORR) 68.2% and duration of response (DOR)
- 1y agoAVBPArriVent BioPharma Reports Second Quarter 2025 Financial ResultsGlobeNewswirePositive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient in the Phase 1
- 1y agoAVBPArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026GlobeNewswireEnrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc.
- 1y agoAVBPArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical
- 1y agoAVBPArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded WarrantsGlobeNewswireNEWTOWN SQUARE, Pa., July 01, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical
- 1y agoAVBPArriVent Announces Investor Event on Firmonertinib Path Forward for EGFR PACC Mutant NSCLCGlobeNewswireNEWTOWN SQUARE, Pa., June 20, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
- 1y agoAVBPArriVent BioPharma Reports First Quarter 2025 Financial ResultsGlobeNewswireCompleted enrollment in global pivotal Phase 3 study for firmonertinib monotherapy in first-line NSCLC harboring EGFR exon 20 insertion mutationsPlanned update for development of firmonertinib in first-line NSCLC PACC
- 1y agoAVBPArriVent BioPharma Appoints Merdad Parsey, M.D., Ph.D. to its Board of DirectorsGlobeNewswireNEWTOWN SQUARE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative
- 1y agoAVBPArriVent BioPharma Reports Full Year 2024 Financial ResultsGlobeNewswireFirst clinical data demonstrating robust confirmed responses and CNS anti-tumor activity for firmonertinib in first-line NSCLC EGFR PACC mutationsGlobal pivotal Phase 3 monotherapy study for firmonertinib in first-line
- 1y agoAVBPArriVent BioPharma Enters Exclusive License with Lepu Biopharma for MRG007, an Antibody Drug Conjugate for the treatment of Gastrointestinal CancersGlobeNewswireExclusive global license outside of Greater China for MRG007, a novel antibody drug conjugate (ADC) in development for gastrointestinal (GI) cancersFirst Investigational New Drug (IND) submission planned for 1H
- 1y agoAVBPArriVent BioPharma Reports Third Quarter 2024 Financial ResultsGlobeNewswireRobust firmonertinib monotherapy activity in front-line EGFR PACC mutant NSCLC including in patients with brain metastases Top-line pivotal data from global Phase 3 FURVENT trial for firmonertinib in front-line NSCLC
- 2y agoAVBPArriVent Announces Positive Proof-Of-Concept Global Phase 1b Interim Data for Firmonertinib Monotherapy In First-Line EGFR PACC Mutant Non-Small Cell Lung Cancer At The 2024 World Conference On Lung CancerGlobeNewswire81.8% ORR by BICR and 63.6% confirmed ORR by BICR at the 240 mg dose; 46.2% confirmed ORR in CNS Metastases 90.9% (n = 20/22) of patients with confirmed responses remained on study with a median duration of response not
- 2y agoAVBPArriVent BioPharma Reports Second Quarter 2024 Financial ResultsGlobeNewswireClinical proof-of-concept monotherapy data for once daily, first-line firmonertinib in EGFR PACC mutant non-small cell lung cancer (NSCLC) to be presented as a presidential symposium presentation at the 2024 World
- 2y agoAVBPArriVent to Present Proof-Of-Concept Phase 1b Data for Firmonertinib in EGFR PACC Mutant Non-Small Cell Lung Cancer at the 2024 World Conference on Lung CancerGlobeNewswireFirst-line monotherapy data for once daily firmonertinib selected as an oral presentation in the presidential session First prospectively designed randomized clinical data for a small-molecule EGFR tyrosine kinase
- 2y agoAVBPArriVent Announces a Multi-Target ADC Collaboration with AlphamabGlobeNewswireCollaboration will leverage Alphamab's antibody drug conjugate ("ADC") research and discovery platform and ArriVent's global development and commercialization expertise Upfront and milestone payments to Alphamab worth
- 2y agoAVBPArriVent Appoints John Hohneker, M.D., to its Board of DirectorsGlobeNewswireNEWTON SQUARE, Pa., May 16, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced the
- 2y agoAVBPArriVent BioPharma Reports First Quarter 2024 Financial ResultsGlobeNewswirePresented preclinical firmonertinib (formerly furmonertinib) data at the 2024 American Association for Cancer Research ("AACR") Annual MeetingDosed first patient in Phase 1b combination study of firmonertinib and ICP-189
- 2y agoAVBPArriVent Appoints Kristine Peterson to its Board of DirectorsGlobeNewswireNEWTON SQUARE, Pa., April 22, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc., a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced
- 2y agoAVBPInnoCare Announces Dosing of First Patient in Clinical Study of the Combination of SHP2 Inhibitor ICP-189 and EGFR Inhibitor FurmonertinibBusiness WireInnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company announced that the first patient in China has been dosed in the Phase 1b clinical study of the combination of InnoCare's novel SHP2 (Src
- 2y agoAVBPArriVent BioPharma Reports Full Year 2023 Financial ResultsGlobeNewswireCompany progresses the development of furmonertinib with a data readout planned for 2024Furmonertinib granted Breakthrough Therapy Designation by the U.S. Food and Drug Administration Completed $201 million initial
- 2y agoAVBPArriVent Announces Pricing of Upsized Initial Public OfferingGlobeNewswireNEWTOWN SQUARE, Pa., Jan. 25, 2024 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. ("ArriVent") (NASDAQ:AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical